The Neurologic Impact of COVID-19: Early Signs, Past Experience

Digital latency measures enhance early detection of cognitive decline, revealing neurodegenerative changes before traditional tests indicate impairment.

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

The FDA approved updated dosing for donanemab in early Alzheimer disease, reducing ARIA-E risk by 41% without compromising efficacy.

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

A new study found racial disparities in COVID-19 antiviral prescribing, with clinic site, test type, and telehealth use explaining up to half the gap for Black and Latino patients.

Among recipients of high-dose CVXGA, relative vaccine effectiveness was 67.8% against symptomatic COVID infection at a median 7.3 months post-vaccination.